RESF1 (retroelement silencing factor 1) is a large, unstructured protein involved in epigenetic gene regulation and chr12 remodeling. Functionally, RESF1 regulates imprinted gene expression and maintains repressive epigenetic modifications by recruiting or accumulating SETDB1 to endogenous retroviruses (ERVs) and transposable elements, contributing to ERV silencing in embryonic stem cells through heterochromatin formation [UniProt]. Mechanistically, RESF1 associates with compound G4 quadruplexes in expressed sequences, particularly those linked to ribosomal biogenesis, suggesting roles in transcriptional and translational control 1. Disease relevance is emerging across multiple conditions. RESF1 functions as a tumor suppressor in triple-negative breast cancer; loss of RESF1 significantly increases tumor growth, shortens overall survival, and elevates lung metastasis incidence in mouse models 1. Additionally, a RESF1 polymorphism (rs3207618) is associated with non-response to thalidomide in beta-thalassemia patients 2, while anti-RESF1 autoantibodies appear as novel diagnostic markers in seronegative Sjögren's syndrome, with predictive value for abnormal salivary gland pathology [PMID:37693588; 37]. Clinically, RESF1 represents a potential therapeutic target in cancer management and a biomarker for precision diagnosis in autoimmune disease, though translational applications remain under development.